Recursion Pharmaceuticals, Inc (RXRX)
NASDAQ:RXRX
Want to see RXRX full AI Analyst Report?
RXRX Stock Chart & Stats
$3.78
-$0.34(-4.54%)
At close: 4:00 PM EST
$3.78
-$0.34(-4.54%)
Day’s Range― - ―
52-Week Range$2.77 - $7.18
Previous CloseN/A
Volume5.68M
Average Volume (3M)15.08M
Market Cap
$1.92B
Enterprise Value$1.02B
Total Cash (Recent Filing)$654.47M
Total Debt (Recent Filing)$72.38M
Price to Earnings (P/E)―
Beta3.36
Next Earnings
Aug 11, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding524,677,860
10 Day Avg. Volume20,376,259
30 Day Avg. Volume15,083,208
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue15.44
Enterprise Value/Gross Profit-44.82
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$7.38Price Target Upside95.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$61.22M
Bulls Say, Bears Say
Bulls Say
Proprietary Data & Platform ScaleRecursion's >50PB multimodal dataset and high-dimensional disease maps create a durable data moat for its AI platform. These proprietary assets improve model training, target identification and patient stratification, supporting reproducible program generation and partner value over the next 2–6 months.
Partnership & Milestone TractionMore than $500M of partner inflows and ten delivered milestones provide recurring non-dilutive funding and external validation from large pharma. This durable partnership stream reduces near-term financing pressure and accelerates program advancement and platform adoption over the medium term.
Cost Discipline & Cash RunwayA sustained ~30% YoY reduction in cash opex, $665M on the balance sheet and guidance of < $390M cash opex for 2026 materially extend runway into early 2028. This cost discipline and cash buffer give the company time to realize clinical and partnership inflection points without immediate financing.
Bears Say
Persistent Cash BurnTTM operating cash flow of roughly −$321M and persistent negative free cash flow mean heavy cash burn. The business remains reliant on milestone timing, partner payments or capital markets; delays or shortfalls could force dilutive financing or program rationalization, raising medium-term execution risk.
No Approved Products YetRecursion has yet to commercialize an approved medicine, so product revenue is unproven and current income depends on lumpy collaboration payments. Until approvals or steady product sales occur, durable revenue generation and margin expansion remain uncertain.
Early-stage Clinical & Regulatory UncertaintyKey programs remain early and REC-4881 faces first-in-disease regulatory uncertainty. Open questions on endpoints, population and pivotal design can delay registrational planning and milestone timing, increasing the risk that clinical progress does not translate to timely approvals or payments.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals, Inc’s price range in the past 12 months?
Recursion Pharmaceuticals, Inc lowest stock price was $2.77 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals, Inc’s market cap?
Recursion Pharmaceuticals, Inc’s market cap is $1.92B.
When is Recursion Pharmaceuticals, Inc’s upcoming earnings report date?
Recursion Pharmaceuticals, Inc’s upcoming earnings report date is Aug 11, 2026 which is in 69 days.
How were Recursion Pharmaceuticals, Inc’s earnings last quarter?
Recursion Pharmaceuticals, Inc released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.045.
Is Recursion Pharmaceuticals, Inc overvalued?
According to Wall Street analysts Recursion Pharmaceuticals, Inc’s price is currently Undervalued.
Does Recursion Pharmaceuticals, Inc pay dividends?
Recursion Pharmaceuticals, Inc does not currently pay dividends.
What is Recursion Pharmaceuticals, Inc’s EPS estimate?
Recursion Pharmaceuticals, Inc’s EPS estimate is -0.24.
How many shares outstanding does Recursion Pharmaceuticals, Inc have?
Recursion Pharmaceuticals, Inc has 524,677,860 shares outstanding.
What happened to Recursion Pharmaceuticals, Inc’s price movement after its last earnings report?
Recursion Pharmaceuticals, Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went up 1.78%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals, Inc?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.38 (95.11% Upside)
$7.38 (95.11% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $588.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.39%
12-Months-Change
Fundamentals
Return on Equity
-54.32%
Trailing 12-Months
Asset Growth
2.63%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals, Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple clear positives: a clinical proof of concept (REC-4881), encouraging early clinical safety/PK/PD for REC-1245, first patient dosed for REC-4539, strong partnership traction (> $500M inflows, 10 milestones), platform efficiency gains (≈90% fewer compounds, ~2x faster candidate progression), and a 30% YoY reduction in cash operating expenses with $665M cash (runway into early 2028). The primary negatives are that the programs are still early (key readouts and registrational plans pending), regulatory uncertainty for first-in-disease indications, potential safety risks as dose escalation continues, and a finite runway that could be pressured by delays. Overall, the highlights materially outweigh the lowlights given the combination of clinical proofs, platform progress, partnership milestones, and cost discipline.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$7.38
▲(95.11% Upside)
Technical Analysis
Ownership Overview
2.88% Insiders
12.35% Mutual Funds
24.07% Other Institutional Investors
35.10% Public Companies and Individual Investors